



Annual Report

2022





CONTENTS

Letter From the CEO	2
The World Reopens	6
Advancing ISPOR's Mission	8
ISPOR's Members	18
Strategic Initiatives	22
The Future of ISPOR and HEOR	26
Contribute to the ISPOR Mission	28
Financials	30
Leadership	32

Letter From the CEO

This has been a year to remember. In many ways, ISPOR has successfully moved through and beyond the pandemic with a return to in-person events for our 2 annual conferences, ISPOR 2022 and ISPOR Europe 2022. This also has been a highly productive year for the Society. ISPOR published 10 new ISPOR Reports, including an update of our most downloaded Good Practices Report, CHEERS 2022. The Society published its 2022-2023 Top 10 HEOR Trends report and launched the new HEOR News Desk. ISPOR responded to 13 public calls for comment over the year, supporting the use of HEOR in policy and guidance documents. ISPOR also continued to organize summits, roundtables, short courses, webinars, and member group meetings. An overview of many of the milestones in 2022 is featured in the next section.



It has also been a bittersweet year for me personally, as it is my last full year serving as ISPOR's CEO and Executive Director. I announced my plans to retire in 2022. It has been an honor and a privilege to lead ISPOR during my tenure. I will continue to follow the Society and its members as the discipline of HEOR continues to have a profound impact on improving healthcare decisions.

In closing, I would like to offer my sincere gratitude to the global HEOR community for the work that you do. Your work matters. Thank you for everything that you do to inform and improve healthcare decision making around the globe.

Nancy S. Berg

Nancy S. Berg

Chief Executive Officer and Executive Director

ISPOR—The Professional Society
for Health Economics and Outcomes Research



2022 KEY MILESTONES

CONFERENCES

ISPOR 2022 and ISPOR Europe 2022

RETURNED TO IN-PERSON EVENTS

8926

TOTAL CONFERENCE/SUMMIT EVENT
REGISTRATIONS

96


COUNTRIES REPRESENTED AT EVENTS



EVENTS

THE SOCIETY ORGANIZED
AND HELD:

- 2 ANNUAL CONFERENCES, ISPOR 2022 AND ISPOR EUROPE 2022, HELD IN-PERSON
- 1 ASIA PACIFIC SUMMIT
- 1 PAYER SUMMIT
- 5 HTA ROUNDTABLES
- 3 PATIENT ENGAGEMENT ROUNDTABLES
- 51 SHORT COURSES
- 4 SIGNAL EPISODES
- 39 WEBINARS WITH 15,926 REGISTRATIONS





PUBLISHING

10

NEW ISPOR REPORTS
(4 OF WHICH WERE GOOD PRACTICES REPORTS) IN *VALUE IN HEALTH*

This included publishing an update of ISPOR’s most downloaded Good Practices Report: “Consolidated Health Economic Evaluation Reporting Standards 2022” (*CHEERS 2022*)—ISPOR’s most downloaded Good Practices Report



NEWS

MEMBERSHIP GREW:

19,000

INDIVIDUAL AND CHAPTER MEMBERS REPRESENTING 111 COUNTRIES ACROSS THE GLOBE

ISPOR CEO

Nancy Berg

ANNOUNCED HER PLANS TO RETIRE



OFFERINGS

NEW CONTENT AND OFFERINGS INCLUDED:

- 2022-2023 Top 10 HEOR Trends Report*
- About Real-World Evidence*
- HEOR News Desk



THE WORLD REOPENS

The world began to reopen in 2022 after 2 years of pandemic-related shutdowns. In response, ISPOR returned to organizing its 2 annual conferences—ISPOR 2022 and ISPOR Europe 2022—as in-person events (with virtual registration as an option during this transition year). ISPOR's members responded enthusiastically to the return of in-person conferences with registration at both annual conferences rivaling pre-COVID registration highs.


This year was also one in which health economics and outcomes research (HEOR) continued to grow in importance. The pandemic revealed and shined a light on many healthcare issues, including health equity, healthcare costs, financing of innovation, and public health. HEOR is uniquely positioned to address and inform these monumental challenges. And ISPOR's members are uniquely qualified to lead innovation in healthcare fueled by HEOR.

The first plenary of ISPOR Europe 2022 explored the convergence of health technology assessment and regulation.



ADVANCING ISPOR'S MISSION

The Society advances its mission to promote HEOR excellence to improve decision making for health through many channels.



Conferences and Events

ISPOR 2022

The Society's first in-person event since the pandemic, ISPOR 2022, was held May 15-18 in the Washington, DC, USA area with the theme, "The Future of HEOR in Patient-Driven Digital Healthcare Systems." More than 3600 delegates attended ISPOR's annual, international conference representing 70+ countries. During this year of transitioning back to in-person, this conference was also offered with a virtual registration option.

ISPOR EUROPE 2022

ISPOR Europe 2022 was held 6-9 November in Vienna, Austria with the theme, "Collaborating Across Borders: Building & Using Evidence to Enable Access." More than 5000 delegates attended the conference representing 80+ countries. This conference was also offered with a virtual registration option during this transition year.

VIRTUAL ISPOR ASIA PACIFIC SUMMIT 2022

As the world continues to adjust to returning from pandemic shutdowns, ISPOR maintained its regional connections with virtual events. An example of this is the ISPOR Asia Pacific Summit 2022, which was held virtually to optimize the number of delegates who could benefit from the conference. The Summit theme was "Linking HEOR Research, Evidence, and Patient Needs for Decision Making in Asia Pacific."

SIGNAL SERIES

Four *Signal* episodes were held throughout the year that explored topics that will shape healthcare decision making over the next decade. Topics included "The New Science of Cause and Effect," "New Analytical Approaches," "Real Experience Revolution," and "New Insights Into Advanced Therapy Medicinal Products Valuation."

PAYER SUMMIT

The Society organized its third annual Payer Summit in September with the theme, "Value Interpretation: Do We Need to Expand the Concept of Value for High-Cost Innovations?" ISPOR Payer Summits introduce key decision makers to important topics within HEOR and provide insight into their value in healthcare decision making.



“ THE SOCIETY'S FIRST IN-PERSON EVENT SINCE THE PANDEMIC, ISPOR 2022, WAS HELD MAY 15-18 IN WASHINGTON, DC, USA.”

Education

HEOR SHORT COURSE PROGRAM

During the 2 years of the pandemic that prevented in-person events, ISPOR's [HEOR Short Course Program](#) was offered virtually for the first time. In 2022, as the Society's annual conferences returned to in-person, ISPOR also resumed offering its renowned Short Course Program in person immediately prior to the initiation of ISPOR 2022 and ISPOR Europe 2022. The 2 years of virtual courses proved to be in high demand by members, so ISPOR is continuing to offer virtual short courses in addition to in-person courses to make this essential education available to as many HEOR professionals as possible. This year, the Society offered 51 short courses with 1205 course registrations from attendees in 68 countries. Ten new short course topics were also added to the program in 2022.

WEBINARS

ISPOR continued to offer a robust series of topical webinars in 2022 with 39 total webinars attracting more than 15,900 registrations, both members and nonmembers. This year's webinars touched on a wide variety of compelling topics, including health technology assessment, data privacy and digital health, value assessment, healthcare financing, innovative therapies, clinical outcomes assessment, and patient-centered research.

“THE 2 YEARS OF VIRTUAL [SHORT] COURSES [DURING THE PANDEMIC] PROVED TO BE IN HIGH DEMAND BY MEMBERS.”



Roundtables

HEALTH TECHNOLOGY ASSESSMENT ROUNDTABLES

ISPOR held 5 Health Technology Assessment Roundtables in 2022 focusing on the regional areas of Asia Pacific, Europe, Latin America, Middle East and Africa, and North America. These Roundtables provide an important forum that allows for assessors to better understand the importance and use of HEOR in assessments and decision making.

PATIENT ROUNDTABLES

In 2022, the Society organized 3 Patient Representatives Roundtables for Europe, Latin America, and North America.




Publications

VALUE IN HEALTH

ISPOR's flagship journal, *Value in Health*, continues to be the premier journal in HEOR. The journal is included in several of the leading scientific indexes and ranks 9th of 88 journals in Health Policy & Services, 18th of 109 journals in Health Care Sciences & Services, and 50th of 381 journals in Economics. *Value in Health* has a 5.156 impact factor for 2022 and a 5-year impact factor of 6.779. In addition to its 12 monthly issues, the journal featured 4 themed sections over the year, including Artificial Intelligence in March, EQ Health and Wellbeing in April, COVID-19 in May, and Remote Patient Monitoring in June.

VALUE IN HEALTH REGIONAL ISSUES

Value in Health Regional Issues publishes articles from (1) Asia; (2) Central and Eastern Europe, Western Asia, and Africa; and (3) Latin America. In 2022, the journal began publishing 6 issues a year with each issue featuring articles from all regions.




VALUE & OUTCOMES SPOTLIGHT

ISPOR's bimonthly magazine, *Value & Outcomes Spotlight*, features HEOR articles for the global HEOR community. Issues in 2022 included a variety of topical themes, including The Power of Patient Advocacy (Jan/Feb), Moving the Needle on Health Policy (Mar/Apr), The Societal Impact of COVID-19 (May/Jun), Improving Health Equity Through HTA (Jul/Aug), Valuing the Health of Children (Sep/Oct), and Global Price Transparency (Nov/Dec).

HEOR NEWS DESK MICROSITE

ISPOR launched its [HEOR News Desk](#) microsite in 2022. The microsite selects and aggregates global news related to HEOR from around the world. The site is designed for anyone with an interest in HEOR and is freely accessible to all.

“ISPOR LAUNCHED ITS HEOR NEWS DESK MICROSITE IN 2022.”



ISPOR Reports

ISPOR published a staggering number of [ISPOR Reports](#) in *Value in Health* for a total of 10 published reports in 2022. Among this year's Good Practices Reports is an update of the Society's most downloaded report, "Consolidated Health Economic Evaluation Reporting Standards 2022," most commonly referred to as [CHEERS 2022](#).



ISPOR PUBLISHED A STAGGERING NUMBER OF ISPOR REPORTS IN *VALUE IN HEALTH* FOR A TOTAL OF 10 PUBLISHED REPORTS IN 2022.”

1. [Consolidated Health Economic Evaluation Reporting Standards 2022 \(CHEERS 2022\) Statement: Updated Reporting Guidance for Health Economic Evaluation](#)
2. [Opportunities and Barriers to the Development and Use of Open Source Health Economic Models: A Survey](#)
3. [Are We Ready for a New Approach to Comparing Coverage and Reimbursement Policies for Medical Nutrition in Key Markets: An ISPOR Special Interest Group Report](#)
4. [Accounting for Preference Heterogeneity in Discrete-Choice Experiments: An ISPOR Special Interest Group Report](#)
5. [Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force](#)
6. [Machine Learning Methods in Health Economics and Outcomes Research—The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force](#)
7. [Challenges of Health Technology Assessment in Pluralistic Healthcare Systems: An ISPOR Council Report](#)
8. [Is IQWiG's 15% Threshold Universally Applicable in Assessing the Clinical Relevance of Patient-Reported Outcomes Changes? An ISPOR Special Interest Group Report](#)
9. [How Useful Are Digital Health Terms for Outcomes Research? An ISPOR Special Interest Group Report](#)
10. [HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force](#)

2022–2023 Top 10 HEOR Trends Report

ISPOR published the fourth edition of its popular horizon scanning report, 2022-2023 Top 10 HEOR Trends Report. This trends report included a special acknowledgment of the COVID-19 Pandemic as an overarching trend in addition to the traditional 10 featured trends.

OVERARCHING TREND: COVID-19 PANDEMIC

1 REAL-WORLD EVIDENCE

6 DRUG AND HEALTHCARE PRICING

2 VALUE ASSESSMENT

7 PUBLIC HEALTH

3 HEALTH EQUITY

8 HEALTH TECHNOLOGY ASSESSMENT

4 HEALTHCARE FINANCING

9 HEALTH DATA

5 PATIENT ENGAGEMENT

10 ARTIFICIAL INTELLIGENCE



Calls for Comment

The Society routinely communicates the value of HEOR to government leaders and policy makers. In 2022, ISPOR responded to 13 calls for comment over the year that included responses to the US Food and Drug Administration (FDA), EUnetHTA, National Institute for Health and Care Excellence (NICE), and the European Medicines Agency (EMA).

“ IN 2022, ISPOR RESPONDED TO 13 CALLS FOR COMMENT OVER THE YEAR.”

FEBRUARY

US FDA: “Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products Guidance for Industry”

MARCH

US FDA: “Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products; Draft Guidance for Industry”

APRIL

NICE: “NICE Real-World Evidence Framework”

MAY

EUnetHTA: “5/2022 D4.3.2 - Methodological Guideline on Comparators and Comparisons”

AUGUST

EUnetHTA: “8/2022 D4.5 - Applicability of Evidence, EUnetHTA 21”

EUnetHTA: “8/2022 D4.6 - Validity of Clinical Studies, EUnetHTA 21”

EUnetHTA: “8/2022 D4.3.1 Practical Guideline Direct and Indirect Comparisons, EUnetHTA 21”

EUnetHTA: “8/2022 D7.2 Patient and Clinical Expert Guidance, EUnetHTA 21”

EUnetHTA: “8/2022 D7.3 Stakeholder Patient Input Template for Joint Clinical Assessments (JCA), EUnetHTA 21”

SEPTEMBER

US FDA: “Patient Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical”

NOVEMBER

EUnetHTA: “11/2022 D4.4 Endpoints, EUnetHTA 21”

EMA: “Good Practice Guide for the Use of the Metadata Catalogue of Real-World Data Sources, EMA Guidance”

EMA: “Data Quality Framework for EU medicines regulation, EMA Guidance”



ISPOR'S MEMBERS

As a membership society, ISPOR's members are truly the heart of the organization. The Society has grown significantly from the 240 members of its founding more than 25 years ago. ISPOR currently has more than 19,000 individual and chapter members representing 111 countries. As a global organization, the Society has 84 regional chapters that span across Africa, Asia, Europe, Latin America, the Middle East, North America, and Oceania. ISPOR's 143 student chapters span the same regions across the globe.



**MEMBERS ARE ISPOR; ISPOR IS THE HEART OF HEOR;
AND HEOR IS THE FOUNDATION FOR IMPROVING HEALTHCARE DECISIONS.**

19,000+
INDIVIDUAL AND
CHAPTER MEMBERS

84
REGIONAL CHAPTERS

143
STUDENT CHAPTERS

111
COUNTRIES

ISPOR—A Multistakeholder Organization





THE SOCIETY'S TASK FORCES WERE QUITE PRODUCTIVE THIS YEAR, PUBLISHING 4 ISPOR GOOD PRACTICES REPORTS OVER THE YEAR."

Task Forces

The Society's task forces were quite productive this year, publishing 4 ISPOR Good Practices Reports over the year, including "[Consolidated Health Economic Evaluation Reporting Standards 2022 \(CHEERS 2022\) Statement: Updated Reporting Guidance for Health Economic Evaluation](#)," "[Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force](#)," "[Machine Learning Methods in Health Economics and Outcomes Research—The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force](#)," and "[HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force](#)."

Four new task forces were initiated in 2022, including [Structured Expert Elicitation for Healthcare Decision Making](#), [Use of Electronic Health Records for Health Technology Assessment](#), [Valuing HRQoL of Children and Adolescents in Economic Models \(Pediatric Utilities\)](#), and [Value-Based Healthcare Implementation Special Task Force](#).

Special Interest Groups

In 2022, ISPOR's 15 special interest groups included [Biosimilars](#), [Clinical Outcome Assessment](#), [Digital Health](#), [Health Equity Research](#), [Health Preference Research](#), [Medical Devices and Diagnostics](#), [Medication Adherence and Persistence](#), [Nutrition Economics](#), [Oncology](#), [Open Source Models](#), [Patient-Centered](#), [Precision Medicine and Advanced Therapies](#), [Rare Disease](#), [Real-World Evidence](#), and [Statistical Methods in HEOR](#). The Society's special interest groups also published 5 ISPOR Reports over the year in *Value in Health*, including "[Opportunities and Barriers to the Development and Use of Open Source Health Economic Models: A Survey](#)," "[Are We Ready for a New Approach to Comparing Coverage and Reimbursement Policies for Medical Nutrition in Key Markets: An ISPOR Special Interest Group Report](#)," "[Accounting for Preference Heterogeneity in Discrete-Choice Experiments: An ISPOR Special Interest Group Report](#)," "[Is IQWiG's 15% Threshold Universally Applicable in Assessing the Clinical Relevance of Patient-Reported Outcomes Changes? An ISPOR Special Interest Group Report](#)," and "[How Useful Are Digital Health Terms for Outcomes Research? An ISPOR Special Interest Group Report](#)."

Councils

ISPOR's councils serve as advisory bodies to the Board of Directors and include the [Awards Council](#), [Education Council](#), [Faculty Advisor Council](#), [Global Engagement Council](#), [Health Science Policy Council](#), [Health Technology Assessment Council](#), [Institutional Council](#), [Past Presidents Council](#), and [Patient Council](#). Additionally, the Health Technology Assessment Council published an ISPOR Report in the June issue of *Value in Health*, "[Challenges of Health Technology Assessment in Pluralistic Healthcare Systems: An ISPOR Council Report](#)."

Global Groups

ISPOR continued to fulfill its mission globally through its consortia, networks, chapters, and other member groups. In fact, the Society's more than 19,000 regional and chapter members, 84 regional chapters, and 143 student chapters span more than 110 countries.

The Society's regional chapters are vital in advancing ISPOR's mission at the local level by supporting the use of HEOR to inform effective health policy. Just a few examples of this in 2022 include:



Chile Chapter members participated in discussions with their Ministry of Health to provide guidance around ongoing national health reforms and health services' payment.



Leaders of the **Austria Chapter** served on their country's COVID advisory board that used machine learning to predict health outcomes, costs, and occurrences.



Members from the **Egypt Chapter** and **Jordan Chapter** contributed to the development of their countries' respective national guidelines.



Ethiopia Chapter members worked with their Ministry of Health to develop a roadmap for HTA in the country.



STRATEGIC INITIATIVES

ISPOR's strategic initiatives are outlined in its [Strategic Plan Update 2024](#) and [Science Strategy](#). A number of strategic initiatives were marked with significant progress and/or milestones throughout 2022.

Real-World Evidence

The Society featured nearly 300 conference and poster sessions focused on real-world evidence (RWE) over the year. ISPOR also launched new [About Real-World Evidence](#) web content as part of its [RWE microsite](#) with explanatory content that includes articles, an infographic, a series of videos, and on-demand media training sessions. Real-World Evidence is an [ISPOR Science Strategy](#) theme, and the [2022-2023 Top 10 HEOR Trends Report](#) also featured RWE as the #1 trend. The Society published a new Good Practices Report on RWE this year, "[HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force](#)." The RWE Special Interest Group was active organizing a webinar and journal club in 2022. And the [Real-World Evidence Transparency Initiative](#) continues to foster establishing a culture of transparency for RWE studies to build trust in RWE studies.

Health Technology Assessment

The Society featured more than 350 conference and poster sessions centered on health technology assessment (HTA) in 2022 with the first plenary of ISPOR Europe focusing on the convergence of HTA and regulation. Health Technology Assessment is an [ISPOR Science Strategy](#) theme. For the first time since publishing the ISPOR Top 10 HEOR Trends Report, HTA appeared on the list as the [#8 trend](#). Two ISPOR Reports on HTA were published this year, including "[Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report](#)

of a Joint HTAi/ISPOR Task Force” and “Challenges of Health Technology Assessment in Pluralistic Healthcare Systems: An ISPOR Council Report.” Five Health Technology Assessment Roundtables were held over the year with regional focus on Asia Pacific, Europe, Latin America, Middle East and Africa, and North America. The Society also continued to offer its [HTA Central](#) microsite that is a comprehensive repository of resources and tools to support health technology assessment.

Economic Evaluation

The Society featured more than 1450 conference and poster sessions focused on economic evaluation in 2022. Economic Evaluation is an [ISPOR Science Strategy](#) theme. The Society’s most downloaded ISPOR Good Practices Report was updated and published, “[Consolidated Health Economic Evaluation Reporting Standards 2022](#),” also known as CHEERS 2022. ISPOR also developed a [CHEERS 2022 resource webpage](#) that offers information, a downloadable checklist, and a series of informational videos to support the guidance.

Value Assessment

ISPOR has done much work over the years on value assessment that is summarized on its [Value Assessment Frameworks](#) webpages. The April issue of *Value in Health* featured a fresh look at this work with the article, “[The History and Future of the ‘ISPOR Value Flower’: Addressing Limitations of Conventional Cost-Effectiveness Analysis](#).” The article explored the history of the value flower, described recent developments, and considered implications for future value assessments. ISPOR also supported value assessment by featuring the topic as a main theme of the ISPOR Europe 2022 conference, which focused on “Collaboration Across Borders: Building and Using Evidence to Enable Access” with a goal of furthering coordinated value assessment across jurisdictions.

Patient Engagement

ISPOR’s long-standing commitment to engaging patients in healthcare research and decision making is summarized on its [Patient Engagement in HEOR](#) webpage. In 2022, the Society held more than 650 conference and poster sessions focused on patient-centered research and patient engagement. The third plenary of ISPOR 2022 was “The Patient (Finally) at the Center: How Can We Leverage Digital Data to Make Patient-Focused Adoption, Reimbursement and Management Decisions?” and the second plenary of ISPOR Europe 2022 was “Real-World Patient-Centered Research: Is It Possible Across Countries?” *Value in Health* published its June issue with the themed section of [Remote Patient Monitoring](#). *Value & Outcomes Spotlight’s* January/February issue was centered on [Patient Advocacy: The Growing Voice of Healthcare](#). ISPOR held 3 [Patient Representatives Roundtables](#) over the year. The roundtables focus respectively on Europe, Latin America, and North America.

Payer Engagement

ISPOR has engaged the payer community for many years with much of the Society's work summarized on its [Payer Engagement in HEOR](#) webpage. In September 2022, ISPOR held its third Payer Summit with the theme, "Value Interpretation: Do We Need to Expand the Concept of Value for High-Cost Innovations?" ISPOR's work in health technology assessment (HTA) also serves the payer audience. In 2022, this included 5 HTA Roundtables that focused respectively on the regions of Asia Pacific, Europe, Latin America, Middle East and Africa, and North America.

“ THE ISPOR 2022-2023 TOP 10 HEOR TRENDS REPORT, FOR THE FIRST TIME, FEATURED HEALTH EQUITY AND ADDRESSING DISPARITIES IN HEALTHCARE AS THE #3 TREND.”

Health Equity

Health equity has risen as an issue of interest with the pandemic laying bare many long-standing issues of equity in healthcare. The [ISPOR 2022-2023 Top 10 HEOR Trends Report](#), for the first time, featured Health Equity as the #3 trend. ISPOR 2022 focused on health equity with its second plenary, "Can Big Data Analytics Deliver on the Promises of Personalized Medicine for All? Unpacking the Health Equity Considerations." The July-August issue of *Value & Outcomes Spotlight* editorial was themed with "Efficiency Versus Health Equity in HTA." ISPOR's [Health Equity in Research Special Interest Group](#) also has been active throughout the year.

Digital Health

The growth and impact of digital health has exploded with the expansion of digital technology and data. [ISPOR's 2022-2023 Top 10 HEOR Trends Report](#) featured Artificial Intelligence as the #10 trend. Several ISPOR Reports published over the year touched on digital health, including "[Machine Learning Methods in Health Economics and Outcomes Research—The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force](#)" and "[How Useful Are Digital Health Terms for Outcomes Research? An ISPOR Special Interest Group Report.](#)" *Value in Health* featured a themed section in its March issue, [Artificial Intelligence](#). And ISPOR's [Digital Health Special Interest Group](#) continues to focus on digital health issues.

Low- and Middle-Income Countries

ISPOR has a long history of commitment to low- and middle-income countries (LMICs) that are outlined in its [LMIC webpage](#), and well over half of ISPOR's regional chapters are based in LMICs. LMICs are called out as one of the strategic themes in ISPOR's [Science Strategy](#). The Society advances HEOR globally through its consortia, networks, and chapters and by producing worldwide conferences, training and education, and publications—with *Value in Health Regional Issues* publishing articles focused on LMICs. ISPOR also supports LMICs through its LMIC Health Economics and Outcomes Research Award, membership fee waivers, conference travel grants, and educational funding for chapters.


Diversity, Equity, and Inclusion

One of ISPOR's core organizational values is, "We embrace diversity and inclusion in our membership and in all endeavors." The Society has proactively worked to improve diversity of all types throughout the organization. Much progress has been made. ISPOR does recognize, however, that this requires a consistent, concerted, long-term effort.


The Society's Board of Directors continues to be diverse with a 50/50 gender balance and strong global representation. In 2022, ISPOR's staff comprised 82% females and 18% males (a very common gender mix for staff of associations) with 28% people of color.

The gender diversity of ISPOR's conference speakers has improved significantly since 2016 when only 26% of conference speakers were women. In 2022, 44% of the Society's conference speakers were women. While this is a positive 7-year trend, 2022 numbers dipped from a 2021 high of 49% of women conference speakers. In another positive note, analysis of the acceptance rates of submitted abstracts continues to show that no gender-based selection bias is occurring.

GENDER DIVERSITY METRICS



ISPOR Board of Directors 2022–2023



Female Plenary Speakers — 2016–2022 ISPOR Conferences

THE FUTURE OF ISPOR AND HEOR

HEOR Helps Inform and Improve Healthcare Decisions

As the discipline of HEOR has grown, ISPOR has expanded with it. HEOR continues to increase its influence to inform and improve healthcare decisions as a multitude of global health trends increases the complexity of decision making. The many challenges in healthcare today and in the future will make HEOR even better primed to address these daunting issues.

Amplifying the Impact of HEOR

Moving forward, ISPOR retains a steely focus on continuing to fulfill its mission to promote HEOR excellence to improve decision making globally. A new initiative will be underway starting in 2023 to help amplify the awareness and understanding of HEOR for nonexpert audiences.

The Society's Strategic Blueprints

ISPOR continues to execute its strategy. The ISPOR [Strategic Plan Update 2024](#) and its 4 pillars—Scientific and Research Excellence, Member Engagement, Education and Training, and Communication and Collaboration—guide these efforts. The [ISPOR Science Strategy](#)—tying directly to the Society's mission and Strategic Plan—includes key science themes that guide much of its work. These themes include Real-World Evidence; Economic Evaluation Methods; Patient-Centered Research; Special Populations and Technologies; HTA in Healthcare Decision Making; Health Economics, Access, and Policy; Low- and Middle-Income Countries; and Resilient Learning Healthcare Systems.

Sunday 6 November

- 07:00 - 17:00 **First Aid Office** Room 0.41, Level 0
- 07:00 - 17:00 **ISPOR Europe 2022 Registration Hours** Entrance Hall, Level 0
- 07:00 - 17:00 **Multi-Faith Prayer Room** Room 0.90, Level 0
- 07:00 - 17:00 **Nursing Mothers' Room** Room 0.91, Level 0
- 07:00 - 17:00 **Speaker Ready Room** Room 0.96-0.97, Level 0
- 07:00 - 17:30 **Cloakroom** Room 0.14-0.16, Level 0
- 08:00 - 12:00 **Short Course Morning Sessions (separate registration required)**
 - 001 Alternative Economic Assessment for Expressing Healthcare Value and Informing Resource Allocation Decisions Room 1.61-1.62, Level 1
 - 002 Elements of Pharmaceutical/Biotech Pricing Hall L3, Level 1
 - 003 Going Beyond the Standard: Exploring Advanced Survival Modeling Techniques Hall E2, Level 0
 - 004 Health Economic Modeling in R: A Hands-on Introduction Hall E1, Level 0
 - 005 Introduction to the Design & Analysis of Observational Studies of Treatment Effects Hall F1, Level 0
 - 006 Understanding Survival Modeling with Application to HTA Hall F2, Level 0
- 08:00 - 17:00 **Short Course Full Day Session (separate registration required)**
 - 007 Reimbursement Systems for Pharmaceuticals in Europe Hall M, Level 1
- 13:00 - 17:00 **Short Course Afternoon Sessions (separate registration required)**
 - 008 Advanced Decision Modeling for Health Economic Evaluations Hall F1, Level 0
 - 009 Applied Cost-Effectiveness Modeling with R Hall E1, Level 0
 - 010 Developing Decision-Grade Real-World Evidence Hall E2, Level 0
 - 011 Introduction to Health Technology Assessment Room 1.61-1.62, Level 1
 - 012 Risk-Sharing/Performance-Based Arrangements in Developing Countries Hall L3, Level 1
 - 013 Statistical Methods for Health Economics & Outcomes Research Hall F2, Level 0

Monday 7 November

- 06:30 - 17:30 **ISPOR Europe 2022 Registration Hours** Entrance Hall, Level 0
- 06:30 - 18:30 **Multi-Faith Prayer Room** Room 0.90, Level 0
- 06:30 - 18:30 **Nursing Mothers' Room** Room 0.91, Level 0
- 06:30 - 19:00 **First Aid Office** Room 0.41, Level 0
- 06:30 - 19:00 **Cloakroom** Room 0.14-0.16, Level 0
- 07:00 - 17:00 **Speaker Ready Room** Room 0.96-0.97, Level 0
- 07:15 - 08:15 **Member Group Meeting** Hall M, Level 1
 - Open Meeting - Oncology Special Interest Group
- 07:30 - 08:30 **Morning Coffee Service** Gallery, Level 1
- 08:30 - 09:45 **Welcome and Plenary Session 1** Hall A, Level 2
 - ISPOR Welcome Remarks
- 10:00 - 11:15 **Concurrent Breakout Session 1**
 - 101 Bringing a Sledgehammer to Crack a Nut: Is There Potential to Use Advanced Methods in Early Health Economic Analyses? Hall N, Level 1
 - 102 Diving into Supporting Clinical Plausibility in Lifetime Survival Extrapolations: The Need for Structured Tools to Guide HTA Submissions Hall E2, Level 0
 - 103 How Can the Voice of the Patient be Better Heard in HTA Decision Making in Rare Diseases? Hall F2, Level 0


KEY: ● In-Person ● Live Streaming ● Virtual ● Available On-Demand

- 104 Improving Health Technology Assessment (HTA) in Eastern Europe and Central Asia: An Expert Debate Hall M, Level 1
- 105 A Workshop on Developing Patient-Centered Real-World Evidence: Consensus Recommendations and Case Examples Virtual | Watch In-Person, Hall L2, Level 1
- 106 Developing a Multi-Stakeholder Shared Learning Forum for Real-World Evidence: A Test and Learn Approach to Reducing Uncertainties Hall E1, Level 0
- 107 Real-World Evidence (RWE) Best Practices: Operationalizing NICES RWE Framework Hall F1, Level 0
- 108 CCVDynamics Virtual | Watch In-Person, Hall L3, Level 1
- 109 Frameworks and Methods for the Design of Stated Preference HEOR Theater 1, Hall X3, Level -2
- 110 Incorporating Informal Care Considerations in HTA HEOR Theater 2, Hall X1, Level -2
- 111 Quantifying Bias in Real-World Studies: A New Hope for RWD Acceptance or Are HTAers Gonna Hate? Hall E1, Level 0 Sponsor: EuroG
- 112 From Cradle to Grave: Can We Predict Patient Health and QoL Consistently Over the Lifespan? Hall E2, Level 0 Sponsor: EuroG
- 113 Health Technology Assessment of Digital Health Technologies Hall F1, Level 0
- 114 Patient-Centered and Rare Disease HTA: A Roadmap for Increasing the Use of Patient-Preference Studies in Decision Making in Health: The Final Recommendation of the ISPOR Using Patient Preferences To Inform Decision Making Special Interest Group
- 115 A Roadmap for Increasing the Use of Patient-Preference Studies in Decision Making in Health: The Final Recommendation of the ISPOR Using Patient Preferences To Inform Decision Making Special Interest Group
- 116 Improving the Quality of Health Economic Evaluations for Healthcare Projects Hall F1, Level 0
- 117 Improving the Quality of Health Economic Evaluations for Healthcare Projects Hall F1, Level 0

- 118 Improving the Quality of Health Economic Evaluations for Healthcare Projects Hall F1, Level 0
- 119 Improving the Quality of Health Economic Evaluations for Healthcare Projects Hall F1, Level 0
- 120 Improving the Quality of Health Economic Evaluations for Healthcare Projects Hall F1, Level 0
- 121 Improving the Quality of Health Economic Evaluations for Healthcare Projects Hall F1, Level 0
- 122 Improving the Quality of Health Economic Evaluations for Healthcare Projects Hall F1, Level 0
- 123 Improving the Quality of Health Economic Evaluations for Healthcare Projects Hall F1, Level 0
- 124 Improving the Quality of Health Economic Evaluations for Healthcare Projects Hall F1, Level 0
- 125 Improving the Quality of Health Economic Evaluations for Healthcare Projects Hall F1, Level 0
- 126 Improving the Quality of Health Economic Evaluations for Healthcare Projects Hall F1, Level 0
- 127 Improving the Quality of Health Economic Evaluations for Healthcare Projects Hall F1, Level 0
- 128 Improving the Quality of Health Economic Evaluations for Healthcare Projects Hall F1, Level 0
- 129 Improving the Quality of Health Economic Evaluations for Healthcare Projects Hall F1, Level 0
- 130 Improving the Quality of Health Economic Evaluations for Healthcare Projects Hall F1, Level 0
- 131 EU Joint Clinical Assessments: What Have We Learned? Sponsor: Luminify
- 132 HTA for Digital Medical Devices Discussion Group
- 133 Health Policy & Regulatory Discussion Group
- 134 Inclusion of the Caregiver Perspective in Health Economic Evaluations for Alzheimer's Disease Hall E1, Level 0 Sponsor: EuroG
- 135 Leveraging Real-World Evidence for Health Economic Evaluations: A Test and Learn Approach to Reducing Uncertainties Hall E2, Level 0
- 136 Things They Didn't Teach You in Grad School: A Real-World Evidence Special Interest Group
- 137 Current Approaches for Biomarkers Value Mapping Health Technology Assessment (HTA) Special Interest Group
- 138 Development of an Evidence-Based Patient-Centered Approach to Promoting the Research in Rare Diseases Hall F2, Level 0
- 139 Are Open-Source Models Really for Healthcare? Hall F2, Level 0
- 140 How Shall We Analyze Change from Baseline? Virtual | Watch In-Person, Hall L2, Level 1
- 141 Not Another Value Framework! Extending the Holistic Value of New Medicines Hall E2, Level 0
- 142 The Main Challenges and Potential Solutions for Combination Therapies in Europe: From Theory to Practice Hall F1, Level 0
- 143 Can Technology Reported Outcomes (TROs) Inform Decision Making? Hall E1, Level 0
- 144 Is There Large Underused Potential in Using Real-World Evidence to Inform Decision Making in Established Therapies? Hall N, Level 1
- 145 Surrogate Analysis in HTA Clinical and Cost-Effectiveness Models Hall F1, Level 0
- 146 Expanding the Toolbox for Preference-Eligible Outcomes Hall M, Level 1
- 147 Improving Accuracy, Validity, and Uncertainty in Health Economic Evaluations Hall F2, Level -2
- 148 Key Trends in HTA Policy: Present and Future Hall M, Level 1
- 149 Poster Tour: LMIC Focused Work Poster Tour
- 150 Poster Tour: Methodology Research in Health Economics Hall F1, Level 0
- 151 Open-Source Model Discussion Group

- 130 - 14:30 **HEOR and Healthcare Decision Making** HEOR Theater 2, Hall X1, Level -2
- 14:30 - 15:15 **Coffee Break** Hall X1-X3, Level -2
- 14:45 - 15:15 **HEOR Theater** HEOR Theater 1, Hall X1, Level -2
- 15:00 - 16:00 **Member Group Meeting** Hall M, Level 1
 - Open Meeting - Real-World Evidence Special Interest Group
- 15:00 - 16:00 **Discussion Groups** Discussion Group
 - 132 HTA for Digital Medical Devices Discussion Group
 - 133 Health Policy & Regulatory Discussion Group
- 15:00 - 16:00 **Educational Symposia**
 - 134 Inclusion of the Caregiver Perspective in Health Economic Evaluations for Alzheimer's Disease Hall E1, Level 0 Sponsor: EuroG
 - 135 Leveraging Real-World Evidence for Health Economic Evaluations: A Test and Learn Approach to Reducing Uncertainties Hall E2, Level 0
- 15:00 - 16:00 **New Professionals Sessions**
 - 136 Things They Didn't Teach You in Grad School: A Real-World Evidence Special Interest Group
- 15:00 - 16:00 **ISPOR Forums**
 - 137 Current Approaches for Biomarkers Value Mapping Health Technology Assessment (HTA) Special Interest Group
 - 138 Development of an Evidence-Based Patient-Centered Approach to Promoting the Research in Rare Diseases Hall F2, Level 0
- 15:15 - 15:35 **HEOR Theater** HEOR Theater 1, Hall X1, Level -2
- 15:30 - 16:00 **Poster Session 1** Hall X2, Level -2
 - (Poster Discussion Period: 15:00 - 16:00)
- 16:30 - 17:30 **Concurrent Breakout Session 2**
 - 139 Are Open-Source Models Really for Healthcare? Hall F2, Level 0
 - 140 How Shall We Analyze Change from Baseline? Virtual | Watch In-Person, Hall L2, Level 1
 - 141 Not Another Value Framework! Extending the Holistic Value of New Medicines Hall E2, Level 0
 - 142 The Main Challenges and Potential Solutions for Combination Therapies in Europe: From Theory to Practice Hall F1, Level 0
 - 143 Can Technology Reported Outcomes (TROs) Inform Decision Making? Hall E1, Level 0
 - 144 Is There Large Underused Potential in Using Real-World Evidence to Inform Decision Making in Established Therapies? Hall N, Level 1
 - 145 Surrogate Analysis in HTA Clinical and Cost-Effectiveness Models Hall F1, Level 0
 - 146 Expanding the Toolbox for Preference-Eligible Outcomes Hall M, Level 1
- 16:30 - 17:30 **Podium Sessions**
 - 147 Improving Accuracy, Validity, and Uncertainty in Health Economic Evaluations Hall F2, Level -2
 - 148 Key Trends in HTA Policy: Present and Future Hall M, Level 1
- 17:30 - 18:30 **ISPOR Welcome Reception** Hall A, Level 2
- 17:45 - 18:30 **Member Group Meeting** HEOR Theater 1, Hall X1, Level -2
 - Open Meeting - Market Access Special Interest Group
- 17:45 - 18:30 **Poster Session 2** Poster Tour
 - 149 Poster Tour: LMIC Focused Work Poster Tour
 - 150 Poster Tour: Methodology Research in Health Economics Hall F1, Level 0
- 17:45 - 18:30 **Discussion Group** Discussion Group
 - 151 Open-Source Model Discussion Group

KEY: ● In-Person ● Live Streaming ● Virtual



CONTRIBUTE TO THE ISPOR MISSION

Join the Global HEOR Community

If you are not yet an ISPOR member, we invite you to join the global HEOR community by becoming a member today. Visit the Society's [Membership](#) webpage to discover the many benefits of membership.

Get Involved

ISPOR members can advance the mission and their careers by getting involved and participating as active members. Visit the [Get Involved](#) webpage to find out how to become more engaged as an ISPOR member.

Partner With ISPOR

Organizations can support the Society mission to improve healthcare decisions and also gain significant visibility within the global HEOR community by partnering with ISPOR through sponsorships, exhibits, and other support opportunities. Visit the [Partnership](#) webpage to find out more.



ISPAR

Financials

Statement of Financial Position

<i>ASSETS</i>	<i>2022</i>	<i>2021</i>
Cash and Cash Equivalents	\$ 2,602,648	\$ 2,100,565
Accounts Receivable, Net	\$ 1,346,131	\$ 179,772
Prepaid Taxes	\$ 1,617	\$ 2,417
Prepaid Expenses, Other	\$ 305,880	\$ 463,735
Investments	\$ 16,716,426	\$ 18,730,120
Property and Equipment, Net	\$ 2,967,182	\$ 3,038,955
TOTAL ASSETS	\$ 23,939,884	\$ 24,515,564
 <i>LIABILITIES AND NET ASSETS</i>		
Accounts Payable and Accrued Expenses	\$ 1,356,901	\$ 361,474
Deferred Revenue	\$ 1,963,730	\$ 438,800
Other Liabilities	\$ 642,442	\$ 685,117
TOTAL LIABILITIES	\$ 3,963,072	\$ 1,485,391
Unrestricted Net Assets	\$ 19,976,812	\$ 23,030,173
TOTAL LIABILITIES AND NET ASSETS	\$ 23,939,884	\$ 24,515,564

Notes

Financial Comments:

During 2022, gross operating revenue increased by 249% from 2021 levels to \$14.39 million, which was due primarily to the return to in-person conferences following the challenges of the pandemic years. Two hybrid conferences (offered in person and virtually), ISPOR 2022 and ISPOR Europe 2022, were successfully delivered with strong financial results. The positive performance of ISPOR conferences and programs combined with diligent management of expenses have allowed the Society to maintain its reserves at levels above the minimum specified in the organization's financial reserves policy (9 months of operating expenses). ISPOR's investment value was affected by the global financial market downturn. Total unrestricted net assets as of December 31, 2022 were \$19.98 million.

Careful financial management at ISPOR continues. Comparisons between the balance sheet of 2022 and 2021 reflect a return to higher volume of business activity and associated financial transactions. Overall, 2022 accounts payable, accrued expenses, and other liabilities are 266% more than 2021 due to associated expenses relating to the conferences. Deferred revenue is higher due to increased advance sales for 2023 conferences. Accounts receivables are higher due to the increased activity from the conferences. The short-term cash position (cash and cash equivalents) held is \$2.6 million, conservatively 24% higher than 2021.


The Society's financial reports are audited annually by CliftonLarsonAllen, LLP.

The final, audited 2022 report will be available in May 2023 and can be provided upon request. Requests for the final report may be made to the Director, Finance and Accounting, Jill Chen via [email](#).

ISPOR has a financial reserve policy to hold the equivalent of 9 months of budgeted expenses in savings to protect the Society in the event of a catastrophic reduction in revenue. The Society is currently in compliance of its financial reserve targets.

Illustration of Activities

December 31, 2022




REVENUE AND SUPPORT 2022

Conferences	\$ 11,138,675
Publications	\$ 1,430,084
Member Services	\$ 1,085,780
Education and Scientific	\$ 736,829
General & Administrative	\$ 62,415

Total Operating Revenue and Support \$ 14,453,784

(Non-Operating Revenue) (\$ 2,421,484)

Total \$ 12,032,300



EXPENSES 2022

Conferences	\$ 6,369,518
Publications	\$ 974,940
Member Services	\$ 4,294,973
Education and Scientific	\$ 557,360
General & Administrative	\$ 2,643,958

Total \$ 14,840,748

Leadership

Board of Directors 2022–2023



Jan Elias Hansen, PhD
President
Genentech
South San Francisco, CA, USA



Isao Kamae, DrPH, MD
Past-President
University of Tokyo
Tokyo, Japan



Brian O'Rourke, PharmD
President-Elect
Brian O'Rourke Health Care
Consulting, Inc
Ottawa, Canada



Beth Devine, PhD
Director
University of Washington
Seattle, WA, USA



Marlene Gyldmark, MPhil
Director
Idorsia Pharmaceuticals Ltd
Basel, Switzerland



Andrea Manca, MSc, PhD
Director
University of York
York, England, UK



Eberechukwu Onukwugha, MS, PhD
Director
University of Maryland
Baltimore, MD, USA



Lotte Steuten, MPhil
Director
Office of Health Economics
London, England, UK



Dong-Churl Suh, PhD
Director
Chung-Ang University
Seoul, South Korea



David Thompson, PhD
Director
Syneos Health
Boston, MA, USA



**Sean D. Sullivan,
BScPharm, MSc, PhD**
Treasurer
University of Washington
Seattle, WA, USA



Nancy S. Berg
CEO and Executive Director
ISPOR—The Professional Society
for Health Economics
and Outcomes Research
Lawrenceville, NJ, USA

Additional information on ISPOR's leadership can be found on the Society's [Our Leaders](#) webpage.





The professional society for health
economics and outcomes research

505 LAWRENCE SQUARE BLVD SOUTH
LAWRENCEVILLE, NJ 08648

P +1-609-586-4981
F +1-609-586-4982

info@ispor.org
www.ispor.org